De Novo Guidance Doesn’t Cut Review Time Enough, Industry Says
This article was originally published in The Gray Sheet
Executive Summary
Industry is skeptical of FDA claims that the plan mapped out in a recent draft guidance on de novo petitions will speed the review process for devices that aren’t a good fit for either the 510(k) or PMA programs.